Besides, baseline characteristics (excluding DAS28-CRP score) did not substantially affect the clinical response to baricitinib in RA patients (379), but a lower DAS28-CRP score at baseline was associated with the achievement of low disease activity (367). This evidence concerns the gene CRP and rheumatoid arthritis.